Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
SYRE Quote, Financials, Valuation and Earnings
Last price:
$33.11
Seasonality move
:
14.35%
Day range:
$32.79 - $34.10
52-week range:
$10.91 - $35.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
701.12x
P/B ratio:
5.63x
Volume:
292K
Avg. volume:
814.3K
1-year change:
41.6%
Market cap:
$2.6B
Revenue:
--
EPS (TTM):
-$2.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.74 | 315.28% | -1.7% | $54.29 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTCT
PTC Therapeutics, Inc.
|
$175.5M | -$1.11 | 11.31% | -28.05% | $81.86 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
$33.05 | $54.29 | $2.6B | -- | $0.00 | 0% | 701.12x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTCT
PTC Therapeutics, Inc.
|
$78.37 | $81.86 | $6.3B | 9.16x | $0.00 | 0% | 3.62x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 2.219 | -- | 10.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTCT
PTC Therapeutics, Inc.
|
161.23% | 0.296 | 8.36% | 2.20x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$56.9M | -28.51% | -28.51% | -- | -$37.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTCT
PTC Therapeutics, Inc.
|
$187.7M | $3.5M | -382.54% | -- | 1.65% | -$322.5M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Spyre Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SYRE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -255.85%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SYRE or NBY?
Spyre Therapeutics, Inc. has a consensus price target of $54.29, signalling upside risk potential of 64.25%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Spyre Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SYRE or NBY More Risky?
Spyre Therapeutics, Inc. has a beta of 3.136, which suggesting that the stock is 213.562% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SYRE or NBY?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or NBY?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns SYRE or OGEN?
Oragenics, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About SYRE or OGEN?
Spyre Therapeutics, Inc. has a consensus price target of $54.29, signalling upside risk potential of 64.25%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 OGENOragenics, Inc.1 0 0 -
Is SYRE or OGEN More Risky?
Spyre Therapeutics, Inc. has a beta of 3.136, which suggesting that the stock is 213.562% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock SYRE or OGEN?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or OGEN?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns SYRE or PTCT?
PTC Therapeutics, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 7.53%. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M -
What do Analysts Say About SYRE or PTCT?
Spyre Therapeutics, Inc. has a consensus price target of $54.29, signalling upside risk potential of 64.25%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $81.86 which suggests that it could grow by 4.45%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 PTCTPTC Therapeutics, Inc.7 5 1 -
Is SYRE or PTCT More Risky?
Spyre Therapeutics, Inc. has a beta of 3.136, which suggesting that the stock is 213.562% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.999%.
-
Which is a Better Dividend Stock SYRE or PTCT?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or PTCT?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 9.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.62x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M PTCTPTC Therapeutics, Inc.3.62x 9.16x $211M $15.9M
-
Which has Higher Returns SYRE or PTN?
Palatin Technologies has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SYRE or PTN?
Spyre Therapeutics, Inc. has a consensus price target of $54.29, signalling upside risk potential of 64.25%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Spyre Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 PTNPalatin Technologies0 0 0 -
Is SYRE or PTN More Risky?
Spyre Therapeutics, Inc. has a beta of 3.136, which suggesting that the stock is 213.562% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SYRE or PTN?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or PTN?
Spyre Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$11.2M is higher than Palatin Technologies's net income of --. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns SYRE or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -28.51% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.18 $455.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About SYRE or TOVX?
Spyre Therapeutics, Inc. has a consensus price target of $54.29, signalling upside risk potential of 64.25%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is SYRE or TOVX More Risky?
Spyre Therapeutics, Inc. has a beta of 3.136, which suggesting that the stock is 213.562% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock SYRE or TOVX?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or TOVX?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$11.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$11.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
